Jubilant Life Sciences, an integrated global Pharmaceutical and Life Sciences Company, has received Abbreviated New Drug Application (ANDA) final approval for Darifenacin Extended-Release Tablets, 7.5 mg and 15 mg, the generic version of Enablex of Allergan Plc, which is used for the treatment of urinary incontinence.
The company has received 6 approvals from the USFDA during the year. As on June 30, 2016, Jubilant Life Sciences had a total of 70 ANDAs for Oral Solids filed in the US, of which 44 have been approved.
Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.
